Progress towards personalized medicine.

Drug Discov Today

Director Biomarker Discovery, Biopharm R&D, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK.

Published: February 2010

Personalized medicine is the tailoring of therapies to defined subsets of patients based on their likelihood to respond to therapy or their risk of adverse events. The advent of improved genomic tools has greatly hastened our understanding of the molecular pathology of diseases, enabling us to redefine disease at the molecular level. The development of molecularly targeted therapies, coupled with improved diagnostic criteria, holds the promise of delivering a new paradigm in drug development. But how far have we come, and how close is personalized medicine to delivering on its promise?

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2009.11.001DOI Listing

Publication Analysis

Top Keywords

personalized medicine
12
progress personalized
4
medicine personalized
4
medicine tailoring
4
tailoring therapies
4
therapies defined
4
defined subsets
4
subsets patients
4
patients based
4
based likelihood
4

Similar Publications

Although radiotherapy techniques are the primary treatment for head and neck cancer (HNC), they are still associated with substantial toxicity, and side effect. Machine learning (ML) based radiomics models for predicting toxicity mostly rely on features extracted from pre-treatment imaging data. This study aims to compare different models in predicting radiation-induced xerostomia and sticky saliva in both early and late stage of HNC patients using CT and MRI image features along with demographics and dosimetric information.

View Article and Find Full Text PDF

Background Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about a third of adults worldwide and is projected soon to be the leading cause of cirrhosis. It occurs when fat accumulates in hepatocytes and can progress to metabolic dysfunction-associated steatohepatitis (MASH), liver cirrhosis, and hepatocellular carcinoma. MASLD pathogenesis is believed to involve a combination of genetic and environmental risk factors.

View Article and Find Full Text PDF

Foundation Models for Translational Cancer Biology.

Annu Rev Biomed Data Sci

January 2025

1Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California, USA;

Cancer remains a leading cause of death globally. The complexity and diversity of cancer-related datasets across different specialties pose challenges in refining precision medicine for oncology. Foundation models offer a promising solution.

View Article and Find Full Text PDF

Treating Opioid Use Disorder and Opioid Withdrawal in the Context of Fentanyl.

Annu Rev Clin Psychol

January 2025

Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; email:

The opioid crisis, driven by illicitly manufactured fentanyl, presents significant challenges in treating opioid use disorder (OUD) and opioid withdrawal syndrome. Fentanyl is uniquely lethal due to its rapid onset and respiratory depressant effects, driving the surge in overdose deaths. This review examines the limitations of traditional diagnostic criteria like those of the , Fifth Edition, Text Revision (DSM-5-TR) and explores the potential of dimensional models such as the Hierarchical Taxonomy of Psychopathology (HiTOP) for a more nuanced understanding of OUD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!